within Pharmacolibrary.Drugs.ATC.V;

model V09IB01
  extends Pharmacokinetic.Models.PK_2C(
    weight         = 70,
    F              = 1,
    Cl             = 3.6666666666666666e-05,
    adminDuration  = 600,
    adminMass      = 185 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.0144,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,            
    Vdp             = 0.0081,
    k12             = 4.5,
    k21             = 4.5
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>V09IB01</td></tr><td>route:</td><td>intravenous</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Indium (111In) pentetreotide is a radiopharmaceutical agent, a radiolabeled somatostatin analog used in diagnostic imaging to localize neuroendocrine tumors, particularly those expressing somatostatin receptors. It is not used for therapy but for somatostatin receptor scintigraphy (OctreoScan), and continues to be clinically approved and utilized, though it is being replaced by newer alternatives in some settings.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters in adult patients (mixed sex) with suspected or confirmed neuroendocrine tumors after a standard imaging dose.</p><h4>References</h4><ol><li><p>Breeman, WA, et al., &amp; Krenning, EP (1995). Effect of dose and specific activity on tissue distribution of indium-111-pentetreotide in rats. <i>Journal of nuclear medicine : official publication, Society of Nuclear Medicine</i> 36(4) 623–627. PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/7699456/&quot;>https://pubmed.ncbi.nlm.nih.gov/7699456</a></p></li><li><p>Savelli, G, et al., &amp; Bombardieri, E (2004). Feasibility of somatostatin receptor scintigraphy in the detection of occult primary gastro-entero-pancreatic (GEP) neuroendocrine tumours. <i>Nuclear medicine communications</i> 25(5) 445–449. DOI:<a href=&quot;https://doi.org/10.1097/00006231-200405000-00004&quot;>10.1097/00006231-200405000-00004</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/15100502/&quot;>https://pubmed.ncbi.nlm.nih.gov/15100502</a></p></li><li><p>Bushnell, D, et al., &amp; Bouterfa, H (2004). Effects of intravenous amino acid administration with Y-90 DOTA-Phe1-Tyr3-Octreotide (SMT487[OctreoTher) treatment. <i>Cancer biotherapy &amp; radiopharmaceuticals</i> 19(1) 35–41. DOI:<a href=&quot;https://doi.org/10.1089/108497804773391658&quot;>10.1089/108497804773391658</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/15068609/&quot;>https://pubmed.ncbi.nlm.nih.gov/15068609</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end V09IB01;
